Eli Lilly announces obesity drug retatrutide achieves weight loss results in late-stage trial
Eli Lilly reported that its investigational obesity drug retatrutide met primary and secondary endpoints in a Phase 3 clinical trial, with patients losing up to 28-30% of body weight in the highest dose group. The company administered the drug as a once-weekly injection. This represents a development in the company's pipeline for next-generation obesity treatments.
8
Divergence score
This event sits in the top 93% of divergence this week. 2 outlets covered it, splitting into 2 framing camps across 1 bias group.
2 camps
1 bias group
The spectrum · how 2 outlets placed this story
LeftCenterRight
Reuters
The Hill
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
The split, in one line
Reuters emphasizes 28% body weight loss as the headline figure; The Hill mentions up to 30 percent while also specifying 28.3% at highest dose. Both confirm endpoint achievement but differ slightly in which statistic leads.
How each outlet covered it
Grouped by political lean
Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight
reuters.com
Reuters6h ago
Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight
New obesity drug from Lilly delivers major weight loss
thehill.com
The Hill51m ago
New obesity drug from Lilly delivers major weight loss
Cross-checked points from across the political spectrum
Fact ledger
Confirmed
Disputed